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Abstract: Quality by design (QbD) is an essential tool in pharmaceutical 
environment for having product/process/method impregnated with quality. 
Now, QbD is the greatest solution to construct quality in all pharmaceutical 
products, while in the same time making it as a part of system is also a key 
challenge for Industry. For understanding of QbD, it is very much essential 
to understand the desire product performance profile [Target product Profile 
(TPP), Target Product Quality Profile (TPQP)] and identify critical quality 
attributed (CQa). Basically, for meeting the product attributes, the product 
formulation and process can be designed on the basis of these stated parameters. 
Nonetheless, this helps in recognizing the effect of raw materials, critical 
material attributes (CMa), critical process parameters (CPP) on the CQas and 
identification and control sources of variability.  The in and out understanding 
for QbD in generic pharmaceutical industry is really vital, because now and 
then FDa is taking firm stand to make mandatory “deadline” for inclusion of 
QbD. Therefore, an attempt has been made to highlight quality by design for 
generic drugs and its implications to pharmaceutical industry.
Keywords: Quality by Design (QbD), Target Product Profile (TPP), Target 
Product Quality Profile (TPQP), Critical Quality attributes (CQa), Critical 
Material attributes (CMa), Critical Process Parameter (CPP).
1. INTRODUCTION
Quality by design (QbD) is nothing but architecting a formulations 
and manufacturing processes which should ensure preplanned product 
specifications. Quality by Design (QbD) is a holistic way towards drug 





bodies to move towards a more scientific and proactive approach. This concept 
appreciates the approach to build quality in, but not testing it (woodcock, 
2004; asmasiddiqua et al, 2013). Quality by Design is a systematic scientific 
approach to improvement and design of products and methods illustrated and 
facilitated through the organisations of the design space (Lionberger, et al, 
2008). woodcock defined QbD had also been a high quality drug product as a 
product free of contamination and repeatedly delivering the therapeutic benefit 
assured in the label to the consumer (Nasr, 2006; yu, 2006).
ICh Q8 defines quality as “The correctness of a drug product for its 
anticipated use. This term includes aspects such as the identity, purity, and 
strength”. a most widely used definition of quality is “Relishing the customers 
by fulfilling their needs and expectations” which may consists of appearance, 
supply, maintainability, performance, consistency, cost effectiveness and total 
customer satisfaction (gawade, et al., 2013; Roy, 2012). It is important that 
quality needs to be built in by design. To achieve a high level of quality, there 
is the necessity of Quality by Design (gawade, et al., 2013). This manuscript 
provides an opportunity to know what exactly Quality by Design means, 
its advantages, application, requirement, and implementation and different 
key steps of QbD.  This manuscript provides advantages, requirement, and 
implementation of QbD for providing a clearer knowledge and scenic view for 
abbreviated new drug applications (aNDas). The objective is to study Quality 
by Design concept and there advantages & application, the implications of 
QbD & area of implication, to study different key steps of QbD as well.
2. HISTORY
This idea was first outlined by well-known quality expert Joseph M. Juran. 
In the late 1990, FDa’s internal discussion began and in the year 2002 the 
concept paper on 21st century good Manufacturing Practice was published 
(Trivedi, 2011). with assistance of several biopharmaceutical companies, 
pilot programs were started to explore QbD application and understandings 
(Roy, 2012). eMa and FDa launched a pilot program with an objective of 
parallel assessment of certain qualities/CMC section like development, design 
space and actual time release testing by both agencies which are relevant to 
Quality by Design (QbD) in March 2011 (Bhatt and Rane, 2011; us Food 
and Drug administration, pharmaceutical cgMPs for the 21st century: a 
risk based approach, 2002). The pilot program aimed at ensuring consistent 
implementation of ICh Q8, Q9, Q10, Q11 guidelines between eu and us in 
the assessment process and to facilitate sharing of regulatory decisions on new 
regulatory concepts. hence, regulatory bodies across the globe are showing 
appreciable interest for QbD (Purohit and shah, 2013,  Patel et al, 2013). 
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3. ADVANTAgeS Of QbD
The QbD concept has numerous advantages. some of the advantages of QbD are 
tabulated in Table 1 (Nasr, 2006; winkle, 2007; Tang, 2013; somma, 2013). 
Basically research has underlined many challenges that may occur in the 
implementation of QbD. These featured challenges specify several areas that 
FDa may consider in order to speed up the QbD adoption. 
Table 1: advantages of QbD
It offers an advanced level of assurance of drug product quality. •	
It offers cost savings and efficiency for the pharmaceutical industry. •	
It increases the transparency of the sponsor understands the control strategy •	
for the drug product to attain approval and ultimately commercialization. 
It makes the scale-up, validation and commercialization transparent, rational •	
and predictable. 
It eases innovation for unmet medical needs. •	
It increases efficiency of pharmaceutical manufacturing processes and reduces •	
manufacturing costs and product rejects. 
It minimizes or eliminates potential compliance actions, costly penalties, and •	
drug recalls. 
It offers opportunities for continual improvement. •	
It provides more efficiency for regulatory oversight.•	
It updates post approval manufacturing changes and regulatory processes. •	
It more focused post approval cgMP inspections.•	
It enhances opportunities for first cycle approval. •	
It assists continuous improvement and reduces the Computer (CMC) •	
supplement.
It enhances the quality of CMC and reduces the CMC review time. •	
Improves information in regulatory submissions.•	
Regulatory flexibility.•	







Implementation of QbD by regulatory bodies
The actions that FDa takes becomes extra noticeable when applied to 
the subdivisions viz. type of drug and adoption level. Options that the Vs FDa 
should consider to ensure QbD implementation are depicted as follows:
4. fDA POLICY OPTIONS
Define and codify Incentives•	 : although the FDa may have faith in that 
there are benefits to advance defining and codifying incentives, from 
conversations with industry, it is clear many companies see this as a 
powerful way to incentivize QbD adoption.
Tangible guidance for QbD execution•	 : Companies, especially in early 
stages of adoption, have identified confusion around what QbD means and 
how to actually execute as a huge challenge.
Mandate:•	  some drug areas, for e.g. several areas inside the generics industry 
(e.g., controlled and modified release drugs), have had many safety matters. 
For drugs such as these, where there is a public health risk due to absence of 
procedure understanding, mandating QbD is a reasonable option.
4.1. Internal fDA change management
1. Consistency of review process (scientific knowledge and quality): The 
desire for a regular review process and well skilled reviewers is common 
throughout industry. The FDa is aware of this need and has been working to 
train and educate reviewers to prepare them to handle QbD applications.
2. Harmonizing QbD approach: There is a need to harmonize QbD practices 
and requirements through FDa including OPs and associated functions e.g. 
compliance and inspectors. The current state where decisions around QbD 
are sometimes called into question or even reversed when areas subsequent 
to operations (OPs) review are involved has the chance of eroding or even 
stopping the momentum around QbD adoption in industry. 
4.2. external change management
Change in communication method:•	  Industry almost universally asked 
for more frequent, “no risk” dialogs with the FDa. The companies who 
participated in the pilot programs felt they have been benefited from the 
increased, and often less formal communications. 
Creating more buy-in (disseminating case):•	  Industry has made a clear 
call for real, tangible examples of what the FDa has actually approved 
or rejected and why. however, there are legal obstacles for the FDa in 
disclosing this information. 
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Improving international harmonization•	 : There are questions around 
whether or not the FDa is responsible for addressing international 
harmonization of QbD acceptance. This is an area worth at least examining 
as the FDa is currently one of the biggest proponents of QbD and the lack 
of international harmonization is one of the biggest challenges raised by 
companies. 
Utilization of third party model:•	  as a means of catalyzing and standardizing 
QbD within industry. There is a call for more substantial direction from 
and interaction with the FDa. 
5. AReAS Of QbD IMPLeMeNTATION
5.1. Clinical Trials
Quality-by-Design (QbD), an idea that has been successful applied in 
the manufacturing, emphasizes building quality into a process from 
the starting.  Applied in clinical development, this approach would 
prospectively examine the objectives of a trial and define critical factors 
(key data and trial processes such as randomization) critical to meet 
there objectives.  Understanding what data and processes required for 
successful trial is essential to subsequently identifying and managing 
important and likely risks to trial quality (http//www.ich.org, 2005). 
These risks would then be managed through tailoring trial design, 
implementation, and sensible, risk-based oversight.  Focusing on critical 
aspects of a trial could also substantially reduce the burden of clinical 
trial conduct by relieving sponsors of a perceived obligation to mitigate 
every potential risk occur by a trial, especially for those activities that 
minimally affect data quality and human subject protection. However, 
the current models for clinical trial design, implementation and 
oversight may have become outmoded and unsustainable in a global, 
complex clinical trial environment (How to apply QbD principles in 
clinical trials?, 2013; Workshops on QbD and quality risk management 
in clinical trials, 2013, http://ctti-clinicaltrials.org).
5.2. Validation
During the past few years, regulatory agencies have placed an increased 
emphasis on pharmaceutical process understanding. The us Food and Drug 
administration’s (Pharmaceutical cgMPs for the 21st Century)—a Risk 
Based approach describes how combining a focus on process understanding 
with a structured risk-assessment process can help develop control strategies 





(2010). similar concepts are also discussed in ICh Q8 (Pharmaceutical 
Development) and International Conference on harmonization (ICh) Q9 
(Quality Risk Management) (http//www.ich.org, 2005 and 2006). Collectively, 
these principles are described as “quality by design” (QbD).
QbD for process includes patient requirements followed by process 
design & development then risk assessment & process design space definition 
and finally control strategy. QbD for analytical methods includes method 
performance requirements followed by method development then risk 
assessment & analytical method design space definition and finally analytical 
method control strategy. QbD for analytical methods method performance 
requirements and analytical method control strategy are correlated with 
control strategy of QbD for process. The whole process followed continuous 
improvement (subrahmanyam, 2006; The application of quality by design to 
analytical methods, 2013, http://www.pharmtech.com/).
6. DeSIgN gOALS Of QbD
The advantages of QbD principles to pharmaceutical development and 
manufacturing have been rang the bell recently. The key steps of QbD in pharm 
industry include – identification of TPP and CQa, defining the product & process 
design space followed by refinement of product design space. Further, the control 
strategies and process validation to be done before regulatory filling. The risk 
assessment should be done while identifying CQa, define the product design 
space & during the process validation. The product should also be characterized 
at the time of defining process design space (subrahmanyam, 2006).
6.1 Target Product Profile (TPP)
Means prospective and dynamic summary of the quality feature of a drug 
product that achieved to assured that the desired quality, and thus the drug 
product safety and efficacy realized (gawade et al., 2013).  a recent guidance 
defining a Target Product Profile (TPP) issued by FDa is the statement of the 
overall intent of the drug design program, and information about the drug at a 
particular time in development given by TPP (Lionberger et.al., 2008).
This includes dosage form and route of administration, dosage form 
strength(s), therapeutic moiety release or delivery and pharmacokinetic 
characteristics (e.g., dissolution and aerodynamic performance) appropriate 
to the drug product dosage form being developed and drug product-quality 
criteria (e.g., sterility and purity) appropriate for the intended marketed 
product (asmasiddiqua et al., 2013; Trivedi, 2011; Roy, 2012).The TPP guides 
formulation scientists to establish formulation strategies and keep formulation 
efforts focused and efficient. TPP is related to identity, assay, dosage form, purity, 
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stability in the label (Lionberger et al., 2008). The TPP provides a statement 
of the overall intent of the drug development program, and gives information 
about the drug at a particular time in development. generally, the main point 
in the drug labeling and element of drug design activities to definite concepts 
intended for insertion in the drug labeling the TPP is organized according to 
this. TPP forms the basis for product design in the ways  Dosage form; Route 
of administration; strength, maximum and minimum; Release/delivery of 
the drug; Pharmacological characteristic; Drug product quality criteria and 
Pharmaceutical elegance (Purohit and shah, 2013; Patel  et al., 2013).
Target Product Quality Profile (TPQP) is a term that is a natural extension 
of TPP for product quality. It is the quality characteristics that the drug product 
should possess in order to reproducibly deliver the therapeutic benefit promised 
in the label (gawade et al., 2013). The target product quality profile (TPQP) 
is a quantifiable alternate for characteristic of clinical safety and efficacy 
this can be applied to design and optimize a formulation and manufacturing 
process (Lionberger et al., 2008). The target product profile (TPP) has been 
defined as a “prospective and self-motivated summary of the quality features 
of a drug product that preferably will be achieved to ensure that the preferred 
quality, and thus the safety and efficacy, of a drug product is realized”. This 
includes dosage form and route of administration, dosage form strength(s), 
therapeutic moiety release or delivery and pharmacokinetic characteristics 
(e.g., dissolution aerodynamic performance) appropriate to the drug product 
dosage form being developed and drug product-quality criteria (e.g., sterility 
and purity) appropriate for the intended marketed product . The concept of 
TPP in this form and its application is novel in the QbD paradigm (Roy, 2012). 
The TPQP is not treated as condition because it includes bioequivalence or 
stability test that are not applicable in batch to batch release.TPQP includes 
only the patient applicable product performance (Trivedi, 2011; Roy, 2012).
6.2 Critical Quality Attributes (CQA)
The IsPe PQLI explained critical quality attributes (CQas) as physical, 
chemical, biological or microbiological attributes or features to assure product 
quality that are required to be guarded (directly or indirectly). ICh Q8 (R1) 
defines CQas as physical, chemical, biological or microbiological properties 
or characteristics to ensure the desired product quality that should be within 
an appropriate limit, range, or distribution (Lionberger et al., 2008; Trivedi, 
2011). The ICh definition of CQa is: “A CQA is a quality attribute (a 
physical, chemical, biological or microbiological property or characteristic) 
that must be controlled (directly or indirectly) to ensure the product meets its 





performed through risk assessment as per the ICh guidance Q9 (Parks, 2012). 
Prior product knowledge, such as the accumulated laboratory, nonclinical 
and clinical experience with a specific product-quality attribute, is the key in 
making these risk assessments (asmasiddiqua et al., 2013).
In addition to defining the requirements to design the product, the 
QTPP will help to identify critical quality attributes such as potency, purity, 
bioavailability or pharmacokinetic profile, shelf-life, and sensory properties 
(http//www.ich.org, 2005). 
Critical quality attributes (CQa) contain  parameters (Purohit and shah, 
2013; workshops on QbD and quality risk management in clinical trials, 2013, 
http://ctti-clinicaltrials.org) such as appearance; particle size; morphic forms; 
water content; residual solvents; organic impurities; assay; inorganic impurities 
(heavy metals & residue on ignition) (Trivedi, 2011; Roy, 2012). 
CQa is used to describe product performance as well as determinants of 
product performance both the aspects (Figure 1). Critical Process Parameter 
(CPP) The desired product quality and process consistency should be achieved 
by measurable input (input material attribute or operating parameter) or output 
(process state variable or output material attribute) of a process step has been 
explained by CPP (Trivedi, 2011). according to this system, there are four 
classes of parameters and attributes (Lionberger et al., 2008; Patel et al., 
(2013)].
figure 1: significance of Quality attributes






Output process state conditions.•	
Critical Process Parameter means when a practical change in that parameter 
can cause the product to failure to meet the TPQP. There, a parameter critical 
nature not depends on how large of a change one is willing to consider. In 
first step, the range of interest is defined in classifying parameters, which 
are potential operating space (POs). The region between the maximum and 
minimum value of interest is POs for each process parameter. This will also be 
considered as the extent of the sponsor’s quality system with respect to these 
parameters (Lionberger et al., 2008). The process parameters can be classified as 
unclassified, Critical and Non-critical. The sensitivity/criticality of unclassified 
process parameters not established/unknown. The critical process parameters 
can cause product to fail to meet the TPQP whereas the known critical process 
parameters doesn’t cause such failure in TPQP within the POs and there is no 
evidence of interaction with in the PaR (Patel et al., 2013). The identification of 
critical and non-critical process parameters are mainly depends on the sensitivity 
of product characteristics to changes in the process parameters [Nosal, 2007); 
us Food and Drug administration, guidance for industry- PaT, 2013).
 6.3 Control Strategy
Control strategy is defined as “a planned set of controls, derived from current 
product and process understanding that assures process performance and 
product quality” (Food and Drug administration  final report on pharmaceutical 
cgMPs for the 21st Century, 2004, http://www.fda.gov; us Food and Drug 
administration guidance for industry: Q10, 2010). Quality Control strategy 
encompasses design space, process controls and specifications. Particularly, 
the control strategy includes (woodcock, 2004; Lionberger et al., 2008): 
Control of raw material attributes (e.g., drug substance, excipients and •	
primary packaging materials) based on an understanding of their impact 
on process-ability or product quality. 
Product specifications •	
Procedural controls •	
Facility controls such as utilities, environmental systems and operating •	
conditions 
Controls for unit operations that have an impact on downstream processing •	
or end-product quality (e.g. the impact of drying on degradation, particle 





a monitoring program (e.g., full product testing at regular intervals) for •	
verifying multivariate prediction models. 
The Control strategy should establish the necessary controls based on patient 
requirements to be applied throughout the whole product life cycle from product 
and process design through to final product, including aPI and Drug Product 
manufacture, packaging and distribution (seely et al., 2014; FDa CDeR draft 
guidance for industry, Q8, 2010).
6.4 Design Space
In the presence of interacting critical process parameters a design space is one 
approach to ensure product quality. The definition of design space is “The 
multidimensional combination and interaction of input variables (e.g., material 
attributes) and process parameters that have been demonstrated to provide 
assurance of quality” (Lionberger et al., 2008; FDa CDeR draft guidance for 
industry, Q8, 2010). 
submission of a design space to FDa is a pathway obtaining the ability to 
operate within that design space without further regulatory approval. a design 
space is a way to represent the process understanding that has been established. 
The benefits of having a design space are clear; one challenge to the effective 
use of a design space is the cost of its establishment (Nasr, 2006; FDa CDeR 
guidance for industry: PaT, 2013).
The various steps to design space are-
1. Identify the unclassified parameters then,
2. applying design of experiments using the unclassified parameters with the 
other fixed unclassified parameters and
3. selection of selected parameters.
6.5 feedback Control and PAT
application of PaT (ICh draft consensus guideline, 2010) may be part of a 
control strategy. ICh Q8(R) identifies one use of PaT as ensuring that the 
process remains within an established design space (us Food and Drug 
administration guidance for industry: Q9, 2010). In a passive process, PaT 
tools provide continuous monitoring of CPP to demonstrate that a process is 
maintained in the design space. In process testing of CMa (Critical Material 
attributes) can also be conducted online or in line with PaT tools. Both of 
these applications of PaT are more efficient ways to detect failures. In a more 
robust process, PaT can enable active control of CPP, and if there is variation 
in the environment or input materials the operating parameters can be adjusted 
to keep the CMa under control to ensure quality (Lionberger et al., 2008).
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a PaT system that combines continuous monitoring of CMa (instead 
of CPP) can potentially be combined with feedback control of process 
parameters to provide an alternative to design space based control strategies. 
a problem with design space is that it can limit flexibility. a design space is 
usually a specified space of process parameters that has been demonstrated 
to provide acceptable quality. There may be sets of process parameters that 
lead to acceptable quality but were not explored in the establishment of the 
design space. Thus, pursuit of a design space can be movement in the opposite 
direction from a flexible and robust manufacturing process. Direct assessment 
of product quality via PaT may support more flexibility and robustness than is 
represented by the design space (Lionberger et al., 2008; us Food and Drug 
administration guidance for industry: Q10, 2010).
6.6 Process Validation
Increased knowledge of the manufacturing method and an expanded process 
design space should provide more manufacturing adjustability during process 
validation. Because the process designs space “assures quality” of the drug 
product, these limits should also provide the basis of the validation acceptance 
criteria.  The margin that demonstrated the acceptable variability in product-
quality and process performance attributes would also serve as the process 
validation acceptance criteria (seely et al., 2014).  The method design space 
has been created, process validation grown into an exercise to determine that
(i) The process will supply a product of satisfactory quality if operated between 
design spaces 
(ii) The small and/or pilot scale systems used to set up the design space exact 
model the accomplishment of the manufacturing scale process. Therefore, 
in the QbD example, abrupt manufacturing excursions that remain between 
the process design spaces should not endanger the success of the validation 
exercise.
6.7 Regulatory filings
The regulatory filing mainly include the acceptable limit for all main and 
detracting operating parameters that describe the process design space and to 
a more restricted operating space typically described for drug products after 
the process design space has been established and validated (us Food and 
Drug administration guidance for industry: Q9, 2010). This filing would also 
involve the refined product design space, explanation of the control strategy, 
output of the validation exercise and strategies for process observing. The QbD 





or expanded change protocols) that would allow future suability in process 
changes with regard to pre-approved standards that have been consent upon 
within the applicant and the agency [Roy, 2012).
7. CONCLUSION
Quality by design is an essential part of the modern approach to pharmaceutical 
quality. Quality by Design (QbD) is unquestionably ready to help an organization 
solve the perennial challenges of drug development and manufacturing. The 
readiness of any organization for QbD begins with an understanding of QbD 
basics, benefits, and barriers to implementation, followed by a readiness 
assessment that can ensure that one has the right mindset, priorities, and 
resources aligned for a successful implementation. This paper highlights the 
use of QbD in aNDas for drug filing structure by implementing a Question 
Based Review (QBR) structure. It’s having the presence in drug development, 
process development, initial writing of labelling, in validation, in clinical 
trials and many more. Industries as well as regulators are making a move 
in geometric progress in bringing quality product by using QbD concept. 
Regulatory bodies across the globe are showing appreciable interest for QbD. 
Therefore, it can be concluded that the success of companies in the near future 
may be a directly impacted by-product of their ability to integrate the concepts 
of QbD. Nonetheless, Quality by Design (QbD) is geared up to help solve the 
challenges of drug development and manufacturing. 
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